Robert H Brown Selected Research

type 2B Limb-girdle muscular dystrophy

4/2019	Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation.
9/2014	A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides.
9/2010	Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression.
9/2004	Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency.
1/2004	Human umbilical cord blood cells differentiate into muscle in sjl muscular dystrophy mice.
12/2003	Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert H Brown Research Topics

Disease

65	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2022 - 05/2002
14	Motor Neuron Disease (Primary Lateral Sclerosis) 01/2022 - 04/2003
8	Chronic Obstructive Pulmonary Disease (COPD) 10/2022 - 02/2004
8	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2021 - 12/2004
7	Disease Progression 10/2022 - 12/2008
7	Miyoshi myopathy 04/2019 - 01/2002
6	type 2B Limb-girdle muscular dystrophy 04/2019 - 12/2003
5	Asthma (Bronchial Asthma) 10/2017 - 02/2004
5	Hereditary Sensory and Autonomic Neuropathies (HSAN) 04/2015 - 11/2002
4	Nervous System Diseases (Neurological Disorders) 01/2022 - 11/2005
4	Frontotemporal Dementia (Semantic Dementia) 01/2022 - 11/2007
4	Weight Loss (Weight Reduction) 11/2019 - 12/2009
4	Muscular Dystrophies (Muscular Dystrophy) 04/2019 - 12/2003
4	Parkinson Disease (Parkinson's Disease) 12/2011 - 06/2004
4	Neuroblastoma 07/2009 - 03/2004
3	Emphysema 10/2022 - 11/2019
3	Neuroinflammatory Diseases 01/2022 - 04/2016
3	Wallerian Degeneration 01/2021 - 07/2012
3	Inflammation (Inflammations) 04/2011 - 03/2009
3	Ischemia 03/2009 - 06/2004
3	Latex Hypersensitivity (Latex Allergy) 03/2005 - 03/2003
2	Gliosis 01/2022 - 12/2013
2	Hereditary Spastic Paraplegia 01/2021 - 05/2002
2	Obesity 01/2020 - 12/2016
2	Lung Diseases (Lung Disease) 11/2019 - 01/2017
2	Dysferlinopathy 04/2019 - 09/2004
2	Paralysis (Palsy) 10/2016 - 04/2016
2	Traumatic Brain Injuries (Traumatic Brain Injury) 04/2016 - 06/2004
2	Distal Myopathies (Distal Muscular Dystrophy) 09/2014 - 06/2011
2	Sarcoma (Soft Tissue Sarcoma) 04/2014 - 11/2010
2	Mitochondrial Diseases (Mitochondrial Disease) 11/2013 - 08/2010
2	Bronchial Spasm 11/2011 - 05/2007
2	Hypersensitivity (Allergy) 05/2010 - 03/2005
2	Alzheimer Disease (Alzheimer's Disease) 11/2007 - 12/2004
2	Hypercapnia 11/2005 - 10/2004
1	Intellectual Disability (Idiocy) 12/2022
1	Pulmonary Emphysema 10/2022
1	Seizures (Absence Seizure) 01/2022
1	Neuromuscular Diseases (Neuromuscular Disease) 01/2022
1	Tay-Sachs Disease 01/2022
1	Demyelinating Diseases (Demyelinating Disease) 01/2022
1	Polyps 01/2022
1	Airway Obstruction (Choking) 10/2021

Drug/Important Bio-Agent (IBA)

20	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2004
16	Superoxide Dismutase-1IBA 01/2020 - 06/2003
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2005
8	DysferlinIBA 04/2019 - 01/2002
8	Superoxide DismutaseIBA 01/2019 - 05/2002
5	CopperIBA 11/2010 - 05/2002
4	SphingolipidsIBA 07/2021 - 11/2002
4	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 11/2012
4	ZincIBA 11/2010 - 05/2002
4	Rubber (Elastica)IBA 05/2010 - 03/2003
4	LatexIBA 05/2010 - 03/2003
3	EnzymesIBA 12/2022 - 11/2005
3	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2022 - 09/2012
3	LeptinIBA 01/2020 - 10/2004
3	Messenger RNA (mRNA)IBA 12/2019 - 11/2007
3	Profilins (Profilin)IBA 10/2016 - 08/2012
3	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 12/2009 - 11/2006
2	DisulfidesIBA 12/2022 - 05/2004
2	Protein Disulfide-IsomerasesIBA 12/2022 - 07/2015
2	Losartan (Cozaar)FDA LinkGeneric 10/2022 - 10/2021
2	Angiotensin Receptor AntagonistsIBA 10/2022 - 10/2021
2	Nerve Growth Factors (Neurotrophins)IBA 01/2022 - 12/2019
2	ArsenicIBA 01/2020 - 11/2019
2	Morphine (MS Contin)FDA LinkGeneric 01/2020 - 12/2016
2	MicroRNAs (MicroRNA)IBA 01/2020 - 04/2016
2	Hormones (Hormone)IBA 01/2020 - 12/2016
2	AnnexinsIBA 01/2017 - 12/2003
2	Choline O-Acetyltransferase (Choline Acetyltransferase)IBA 01/2017 - 12/2009
2	Opioid Analgesics (Opioids)IBA 12/2016 - 12/2015
2	Carbon DioxideIBA 12/2016 - 03/2013
2	Interleukin Receptors (Interleukin Receptor)IBA 04/2016 - 07/2012
2	GoldIBA 02/2013 - 09/2008
2	Methacholine Chloride (Methacholine)FDA Link 01/2013 - 09/2008
2	angiogeninIBA 12/2011 - 04/2006
2	Interleukin-18 (Interleukin 18)IBA 05/2010 - 03/2005
2	Interleukin-13IBA 05/2010 - 03/2005
2	Serine C-PalmitoyltransferaseIBA 11/2009 - 11/2002
2	4-phenylbutyric acid (Buphenyl)FDA Link 04/2009 - 06/2005
2	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2009 - 03/2009
2	Dynactin ComplexIBA 03/2006 - 04/2003
2	CaspasesIBA 06/2005 - 06/2004
1	Biopolymers (Biopolymer)IBA 01/2022
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2022
1	PolyphosphatesIBA 01/2022
1	Untranslated Regions (Untranslated Region)IBA 01/2022
1	DipeptidesIBA 01/2022
1	Conditioned Culture MediaIBA 01/2022
1	Hexosaminidase A (Hex A)IBA 01/2022
1	poly(glycyl-alanyl)IBA 01/2022
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2021
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 10/2021
1	GlycosphingolipidsIBA 01/2021

Therapy/Procedure

8	Therapeutics 01/2022 - 03/2010
3	Positive-Pressure Respiration (Positive End-Expiratory Pressure) 01/2021 - 03/2008
2	Axotomy 01/2021 - 07/2012
1	Aftercare (After-Treatment) 01/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022